Helicobacter pylori infection medical therapy

	Helicobacter pylori infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Gastritis Peptic ulcer disease Gastric adenocarcinoma MALT lymphoma
Causes
Differentiating Helicobacter pylori infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Guideline Recommendation ACG guidelines ESPGHAN and NASPGHAN guidelines
History and Symptoms
Physical Examination
Diagnostic tests Endoscopic tests Nonendoscopic tests
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Helicobacter pylori infection medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Helicobacter pylori infection medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Helicobacter pylori infection medical therapy
CDC on Helicobacter pylori infection medical therapy
Helicobacter pylori infection medical therapy in the news
Blogs on Helicobacter pylori infection medical therapy
Directions to Hospitals Treating Helicobacter pylori infection
Risk calculators and risk factors for Helicobacter pylori infection medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Regimen	Duration	Eradication rates	Comments
Standard dose PPI b.i.d. (esomeprazole is q.d.), clarithromycin 500 mg b.i.d., amoxicillin 1,000 mg b.i.d.	10–14	70–85%	Consider in nonpenicillin allergic patients who have not previously received a macrolide
Standard dose PPI b.i.d., clarithromycin 500 mg b.i.d. metronidazole 500 mg b.i.d.	10–14	70–85%	Consider in penicillin allergic patients who have not previously received a macrolide or are unable to tolerate bismuth quadruple therapy
Bismuth subsalicylate 525 mg p.o. q.i.d. metronidazole 250 mg p.o. q.i.d., tetracycline 500 mg p.o. q.i.d., ranitidine 150 mg p.o. b.i.d. or standard dose PPI q.d. to b.i.d.	10–14	75–90%	Consider in penicillin allergic patients
PPI + amoxicillin 1 g b.i.d. followed by PPI, clarithromycin 500 mg, tinidazole 500 mg b.i.d.	5 5	>90%	Requires validation in North America

PPI = proton pump inhibitor; pcn = penicillin; p.o. = orally; q.d. = daily; b.i.d. = twice daily; t.i.d. = three times daily; q.i.d. = four times daily. *Standard dosages for PPIs are as follows: lansoprazole 30 mg p.o., omeprazole 20 mg p.o., pantoprazole 40 mg p.o., rabeprazole 20 mg p.o., esomeprazole 40 mg p.o. Note: the above recommended treatments are not all FDA approved.

FDA approved regimens are as follows:

1. Bismuth 525 mg q.i.d. + metronidazole 250 mg q.i.d. + tetracycline 500 mg q.i.d. × 2 wk + H2RA as directed × 4 wk.

2. Lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10 days.

3. Omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10 days.

4. esomeprazole 40 mg q.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10 days.

5. Rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 7 days.